3B Future Health Fund — Full Portfolio

Gain Therapeutics develops small molecule drugs for neurodegenerative diseases using an AI-powered drug discovery platform that identifies novel binding sites on disease-related proteins.

AI & Machine LearningBiotechMedical Devices

Co-investorsTiVenture SA

GreenBone develops biomimetic bone substitutes derived from rattan wood for orthopedic surgery applications including trauma repair, bone augmentation, and reconstruction.

BiotechHealthtechMedical Devices

Co-investorsItalian Angels for GrowthCDP Venture Capital

Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.

AI & Machine LearningBiotechDeep TechTrento, IT

Emiliano Biasini(Co-founder)Pietro Faccioli(Co-founder)Giovanni Spagnolli(Co-founder, CTO)Maria Letizia Barreca(Co-founder)Graziano Lolli(Co-founder)

Co-investorsCDP Venture CapitalSeroba Life SciencesV-Bio VenturesVertis SGRVI PartnersClaris Ventures

BiotechPhiladelphia, US

William Hinshaw(Executive Officer, Director)Jeff Sacher(Chief Financial Officer)Matthew Ros(Chief Executive Officer, President and Secretary)

BoardErez Chimovits(Director)inGiovanni Mariggi(Director)inMatthew Foy(Director)

Board seatRoberto De Ponti· per SEC Form D · $122.6M raise · filed Aug 2023

Co-investorsMedicxiOrbiMed

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

BiotechHouston, US

Alice Bexon(Executive Officer)Clifford J. Stocks(Director, Executive Officer)Kamal D. Puri(Executive Officer)Chris Russell(Executive Officer)Russ Hawkinson(Executive Officer)

BoardSteven Gillis(Director)in

Board seatRoberto De Ponti· per SEC Form D

Co-investorsCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersARCH Venture PartnersQatar Investment AuthorityYonjin Venture LLC

Co-investorsBioMedPartners

AnaCardio is a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, including its GOAL-HF1 program for patients with Heart Failure and Reduced Ejection Fraction (HFrEF).

BiotechMedical DevicesStockholm, SE

Co-investorsIndustrifondenNovo HoldingsPureos BioventuresSound Bioventures

Domain Therapeutics develops drug discovery and development therapies that target GPCRs to modulate the immune system, focusing on immuno-oncology and inflammatory diseases.

BiotechDigital Health

Co-investorsCTI Life Sciences Fund L.P.

Epsilogen is a clinical-stage biotech developing antibody therapeutics for oncology based on IgE, IgA and IgG isotypes, each with differentiated immune effector functions.

BiotechHealthtech

Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)Cristina Oliva(Chief Medical Officer)Nick Robbins-Cherry(Chief Financial Officer)Elizabeth Hardaker(Chief Translational Science Officer)

Co-investorsAlbionVCEpidarex CapitalGlobal BioAccess FundNovartis Venture FundUCL Technology FundBioGeneration Ventures

BiotechPlymouth Meeting, US

Niranjan Y. Sardesai(Executive Officer, Director)Laurent Humeau(Director)James Eadie(Director)Samuel Broder(Director)Sangwoo Lee(Director)Casey Cunningham(Director)

iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.

BiotechDeep TechHealthtechMedical Devices

Catherine Pickering(Co-Founder & CEO)inLars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in

Co-investorsInkefVI PartnersXGEN VentureM Ventures

Co-investorsCDP Venture CapitalClaris VenturesElysia CapitalItalian Angels for Growth

Lite Strategy, Inc.

BiotechCrypto & Web3FintechHealthtechSan Diego, US

David M. Urso(Executive Officer)Daniel P. Gold(Executive Officer, Director)Brian G. Drazba(Executive Officer)Mr. File(Chief Executive Officer & Board Member (former CFO))Kevan E. Clemens(Director)Thomas C. Reynolds(Director)

Co-investorsAisling CapitalGSRNew Enterprise Associates (NEA)Vivo Capital

Co-investorsAstellas Venture Management LLCClaris VenturesNeva Sgr.

On Target Laboratories is a company of scientists and researchers focused on cancer surgery, developing products to support surgical oncology.

BiotechHealthtechMedical Devices

Bill Peters(President, Chief Executive Officer, and Board Member)Rod MacLeod(Chief Financial Officer)Tommy Lee(Senior Vice President of Clinical Operations)Catherine Brisson(Vice President of Regulatory Affairs and Quality)Anne Fornicola(Vice President of Chemistry, Manufacturing and Controls)Scott Huennekens(Executive Chairperson)

Co-investorsCerity Partners VenturesElevate VenturesH.I.G. CapitalH.I.G. HealthBridge Partners

PGDx (Personal Genome Diagnostics) develops comprehensive genomic profiling kits and bioinformatics for precision oncology, including tissue-based and liquid biopsy assays that analyze tumor DNA to guide personalized cancer treatment.

BiotechHealthtechMedical Devices

Co-investorsWindham Capital PartnersVensana Capital

QuantuMDx develops point-of-care molecular diagnostics platforms and assays for detecting infectious diseases including sexually transmitted infections, antimicrobial resistance, respiratory viruses, and other pathogens.

Digital HealthHealthtechMedical DevicesNewcastle upon Tyne, GB

Elaine Warburton(Co-Founder and former CEO)

Co-investorsAdjuvoDEFTA Partners

Roca Therapeutics develops first-in-class small molecule therapies for patients with neovascular retinal diseases.

BiotechHealthtechMedical DevicesNice, FR

Obtained U.S.

Co-investorsAMR Action Fund